
AGR2 is a Biomarker of Metastatic Prostate Cancer
4. Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R.
Human homologue of cement gland protein, a novel metastasis
inducer associated with breast carcinomas. Cancer Res 2005;
65(9):3796–3805.
5. Wang Z, Hao Y, Lowe AW. The adenocarcinoma-associated
antigen, AGR2, promotes tumor growth, cell migration, and
cellular transformation. Cancer Res 2008;68(2):492–497.
6. Ramachandran V, Arumugam T, Wang H, Logsdon CD. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival.
Cancer Res 2008;68(19):7811–7818.
7. Brychtova V, Vojtesek B, Hrstka R. Anterior gradient 2: A novel
player in tumor cell biology. Cancer Lett 2011;304(1):1–7.
8. Zhang Y, Ali TZ, Zhou H, D’Souza DR, Lu Y, Jaffe J, Liu Z,
Passaniti A, Hamburger AW. ErbB3 binding protein 1
represses metastasis-promoting gene anterior gradient protein
2 in prostate cancer. Cancer Res 2010;70(1):240–248.
9. Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, Pavlakis N,
Boyer MJ, Stockler MR, Kaplan W, Breit SN, Sutherland RL,
Henshall SM, Horvath LG. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.
Cancer Res 2009;69(19):7696–7703.
10. Bu H, Bormann S, Schafer G, Horninger W, Massoner P,
Neeb A, Lakshmanan VK, Maddalo D, Nestl A, Sultmann H,
Cato AC, Klocker H. The anterior gradient 2 (AGR2) gene is
overexpressed in prostate cancer and may be useful as a urine
sediment marker for prostate cancer detection. Prostate 2011;
71(6):575–587.
11. Zhang Y, Forootan SS, Liu D, Barraclough R, Foster CS, Rudland PS, Ke Y. Increased expression of anterior gradient-2 is
significantly associated with poor survival of prostate cancer
patients. Prostate Cancer Prostatic Dis 2007;10(3):293–300.
12. Maresh EL, Mah V, Alavi M, Horvath S, Bagryanova L, Liebeskind ES, Knutzen LA, Zhou Y, Chia D, Liu AY, Goodglick L.
Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC cancer 2010;10:680.
13. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou
M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R,
Rubin MA, Pienta KJ. Androgen-independent prostate cancer
is a heterogeneous group of diseases: Lessons from a rapid
autopsy program. Cancer Res 2004;64(24):9209–9216.
14. Mocellin S, Keilholz U, Rossi CR, Nitti D. Circulating tumor
cells: The ‘leukemic phase’ of solid cancers. Trends Mol Med
2006;12(3):130–139.
15. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade.
Nat Rev Cancer 2004;4(6):448–456.
16. Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME. Detection
of androgen receptor mutations in circulating tumor cells in
castration-resistant prostate cancer. Clin Chem 2010;56(9):
1492–1495.
17. O’Hara S, Moreno J, Zweitzig D, Gross S, Gomella L, Terstappen L. Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clin
Chem 2004;50(5):826–835.
18. Shaffer D, Leversha M, Danila D, Lin O, Gonzalez-Espinoza R,
Gu B, Anand A, Smith K, Maslak P, Doyle G, Terstappen L,
Lilja H, Heller G, Fleisher M, Scher H. Circulating tumor
cell analysis in patients with progressive castration-resistant
prostate cancer. Clin Cancer Res 2007;13(7):2023–2029.
19. Clark J, Attard G, Jhavar S, Flohr P, Reid A, De-Bono J, Eeles R,
Scardino P, Cuzick J, Fisher G, Parker MD, Foster CS, Berney
D, Kovacs G, Cooper CS. Complex patterns of ETS gene alteration arise during cancer development in the human prostate.
Oncogene 2008;27(14):1993–2003.

9

20. Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV,
Pienta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno JG,
Connelly MC, Terstappen LW, O’Hara SM. Global gene
expression profiling of circulating tumor cells. Cancer Res
2005;65(12):4993–4997.
21. Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P,
Mostert B, Martens JW, Gratama JW, Sleijfer S, Foekens JA.
Molecular characterization of circulating tumor cells in large
quantities of contaminating leukocytes by a multiplex realtime PCR. Breast Cancer Res Treat 2009;118(3):455–468.
22. Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh
FE, Stouthard JM, Dirix LY, van Dam PA, Van Galen A, de
Weerd V, Kraan J, van der Spoel P, Ramirez-Moreno R, van
Deurzen CH, Smid M, Yu JX, Jiang J, Wang Y, Gratama JW,
Sleijfer S, Foekens JA, Martens JW. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors
of metastatic breast cancer patients. Clin Cancer Res 2011;
17(11):3600–3618.
23. Edgell TA, Barraclough DL, Rajic A, Dhulia J, Lewis KJ, Armes
JE, Barraclough R, Rudland PS, Rice GE, Autelitano DJ.
Increased plasma concentrations of anterior gradient 2 protein
are positively associated with ovarian cancer. Clin Sci (Lond)
2010;118(12):717–725.
24. Makawita S, Smith C, Batruch I, Zheng Y, Ruckert F, Grutzmann R, Pilarsky C, Gallinger S, Diamandis EP. Integrated
proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers.
Mol Cell Proteomics 2011;10(10):M111 008599.
25. Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B,
Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross
ME, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus DB,
Mallick P. Quantitative proteomic profiling identifies protein
correlates to EGFR kinase inhibition. Mol Cancer Ther 2012;
11(5):1071–1081.
26. Belsley DA, Kuh E, Welsch RE. Regression diagnostics: Identifying influential data and sources of collinearity. New York:
John Wiley & Sons; 2004. 292 p.
27. Scher HI, Heller G. Clinical states in prostate cancer: Toward a
dynamic model of disease progression. Urology 2000;55(3):
323–327.
28. Matei DV, Renne G, Pimentel M, Sandri MT, Zorzino L, Botteri
E, De Cicco C, Musi G, Brescia A, Mazzoleni F, Valeria T, Detti
S, de Cobelli O. Neuroendocrine differentiation in castrationresistant prostate cancer: A systematic diagnostic attempt. Clin
Genitourin Cancer 2012;10(3):164–173.
29. Cohen SJ, Alpaugh RK, Gross S, O’Hara SM, Smirnov DA,
Terstappen LWMM, Allard WJ, Bilbee M, Cheng JD, Hoffman
JP, Lewis NL, Pellegrino A, Rogatko A, Sigurdson E, Wang H,
Watson JC, Weiner LM, Meropol NJ. Isolation and characterization of circulating tumor cells in patients with metastatic
colorectal cancer. Clin Colorectal Cancer 2006;6(2):125–132.
30. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen.
J Clin Oncol 2003;21(2):383–391.
31. Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis
G, Joly F, Oudard S, Deplanque G, Zanetta S, Fargeot P, Priou
F, Droz JP, Culine S. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without
neuroendocrine differentiation: Results of the French GenitoUrinary Tumor Group (GETUG) P01 trial. Ann Oncol 2011;
22(11):2476–2481.
32. Sobel RE, Sadar MD. Cell lines used in prostate cancer
research: A compendium of old and new lines–part 1. J Urol
2005;173(2):342–359.

The Prostate

10

Kani et al.

33. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM,
Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW,
Gumerlock PH, Resnick MI, Amini SB, Pretlow TG. CWR22:
The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft
agar. Cancer Res 1996;56(13):3042–3046.
34. Sramkoski RM, Pretlow TG II, Giaconia JM, Pretlowv TP,
Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW. A new human prostate carcinoma cell line, 22Rv1.
In Vitro Cell Dev Biol Anim 1999;35(7):403–409.
35. Kozlov G, Maattanen P, Thomas DY, Gehring K. A structural
overview of the PDI family of proteins. FEBS J 2010;277(19):
3924–3936.
36. Huber M, Bahr I, Kratzschmar JR, Becker A, Muller EC,
Donner P, Pohlenz HD, Schneider MR, Sommer A. Comparison of proteomic and genomic analyses of the human breast

The Prostate

cancer cell line T47D and the antiestrogen-resistant derivative
T47D-r. Mol Cell Proteomics 2004;3(1):43–55.
37. Ather MH, Abbas F. Prognostic significance of neuroendocrine
differentiation in prostate cancer. Eur Urol 2000;38(5):535–
542.
38. Aparicio A, Harzstark AL, Lin E, Corn PG, Araujo JC, Tu S,
Pagliaro LC, Millikan RE, Arap W, Kim J, Ryan CJ, Zurita AJ,
Tannir NM, Lin AM, Small EJ, Mathew P, Jones DM, Troncoso
P, Thall PF, Logothetis C. Characterization of the anaplastic
prostate carcinomas: A prospective two-stage phase II trial of
frontline carboplatin and docetaxel (CD) andsalvage etoposide
and cisplatin (EP). J Clin Oncol 2011; (29 Suppl.)abstr. 4666.
39. Angelsen A, Syversen U, Stridsberg M, Haugen OA, Mjolnerod
OK, Waldum HL. Use of neuroendocrine serum markers in the
follow-up of patients with cancer of the prostate. Prostate
1997;31(2):110–117.


